aOne subject
concealed the history of epilepsy and taking magnesium valproate for a
long time.
Table 2 Summary of the key pharmacokinetic (PK) parameters of SHR2554.
Cmax, maximum
plasma concentration; Tmax, time to
Cmax, AUC0-t, area under the
concentration-time to the last quantifiable concentration;
AUC0-∞, area under the concentration-time to infinity;
t1/2, elimination half-life; CL/F, apparent clearance;
VZ/F, apparent volume of distribution
aPK parameters are presented as geometric mean
(geometric coefficient of variation), with the exception of
Tmax, which is presented as median (range)
bIn the SHR2554
administration alone phase the
AUC0-∞of 1 subject could not be accurately calculated due to
AUCt-∞ >20%, so the number of subjects was
16.
cIn the SHR2554 coadministration with rifampin phase
the AUC0-∞ of 2 subjects could not be accurately
calculated due to AUCt-∞ >20%, so the
number of subjects was 15.